GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Basic Sciences/Envbiotics-Front. Med. 2026

Envbiotics-Front. Med. 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated February 1, 2026

Quick Answer

### What Are Envbiotics? Envbiotics is a term that encapsulates the idea of regulating and optimising gut microbiota indirectly by focusing on the environmental conditions of the gut rather than directly modifying microbial populations or supplying nutrients.


### What Are Envbiotics?

Envbiotics is a term that encapsulates the idea of regulating and optimising gut microbiota indirectly by focusing on the environmental conditions of the gut rather than directly modifying microbial populations or supplying nutrients. Unlike prebiotics, which act as substrates for gut microbes, or postbiotics, which focus on metabolic by-products of microbes, Envbiotics emphasises non-nutritional factors that shape the gut microenvironment. These factors include:

1. **Physicochemical Conditions**:

  • Intestinal acidity
  • Oxidation-reduction potential
  • Osmotic balance
  • Temperature
  • Ion concentrations
  • Bile salts
  • Short-chain fatty acids

2. **Spatial Factors**:

  • The arrangement and integrity of the intestinal mucosal layer
  • The volume and composition of host mucus secretion

3. **Biological Markers**:

  • Levels of antimicrobial peptides
  • Immune cell functions
  • Presence of other symbiotic organisms

### Why Envbiotics Are Important

The concept of Envbiotics addresses limitations in the current understanding of gut microbiota modulation. While prebiotics and postbiotics focus on nutrient-based or microbial by-product-based interventions, they often neglect the role of the gut's environmental conditions in shaping microbial behaviour. Envbiotics fills this gap by recognising that non-nutritional factors can profoundly influence the survival, colonisation, and function of gut microbes.

### Key Research Supporting Envbiotics

1. **Medications and Gut Microbiota**:

Studies have shown that common medications, such as antidepressants, antipsychotics, and beta-blockers, can significantly alter gut microbiota by affecting the host's physiological state, even though these drugs are not directly metabolized by the microbes.

2. **Host-Microbe Interactions**:

Host-derived factors such as mucin (e.g., MUC2) and proteins like FABP2 play critical roles in shaping microbial communities. For instance, disruptions in mucin production can lead to increased intestinal permeability and dysbiosis.

3. **Non-Nutritional Interventions**:

  • Acupuncture has been shown to regulate vagal activity, thereby influencing gut microbiota indirectly by modulating host immune status and digestive gland function.
  • Composite formulations like xyloglucan and pea protein have been reported to enhance intestinal barrier function and regulate microbiota homeostasis by forming a mechanical barrier in the mucosal layer.

4. **Biological Compounds**:

  • Pyrroloquinoline quinone (PQQ), a redox enzyme cofactor, selectively enriches beneficial bacteria by modulating the host's immune system and gut microenvironment, rather than acting directly on microbial populations.
  • Exosomes and vesicle-like components derived from plants or other sources influence gut microbiota indirectly by modulating host immune responses.

### Envbiotics as a Future Research Direction

The concept of Envbiotics represents a paradigm shift in gut microbiota research and therapeutic approaches. By focusing on the environmental conditions critical for microbial survival and performance, Envbiotics offers a more holistic framework for understanding and optimizing host-microbe interactions. This approach could lead to:

  • Improved strategies for restoring gut microbiota balance in conditions like colitis, Crohn's disease, and dysbiosis.
  • Development of non-pharmaceutical interventions that enhance host health by optimizing the gut microenvironment.
  • A better understanding of how non-nutritional factors, such as stress, immune status, and external interventions, influence gut microbiota.

### Conclusion

It highlights the importance of environmental modulation as a distinct pathway for regulating microbial communities and improving host health. If new developments in Envbiotics are published in 2026, they are likely to build on the foundational principles outlined here, offering deeper insights into the interplay between the gut microenvironment and microbiota.

Related Q&A

ARID1A Loss Drives ICC Development: Hepatology | June 2026

Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...

Blocking Succinate–GPR91 Signaling in MASH: Hepatology | April 2026

Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...

THRSP–MIF Signaling Drives MASH Progression: Hepatology | April 2026

Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...

Butyrate and Butyrate-Producing Bacteria in CKM: Antioxidants | July 2026

Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...

CK7, CK20, and CDX2 Refine Prognosis in Small Intestinal Adenocarcinoma: Annals of Oncology | 2026

• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...

Fatty Liver Drives Hyperglycemia Through Liver–Gut Signaling : Cell Metab | Jun 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer